Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS)
Keywords
Abstract
Description
IRIS study is an Italian, multicenter, prospective and non-interventional study aimed to observe the safety and efficacy of uninterrupted or shortly interrupted catheter ablation procedure with Rivaroxaban in nonvalvular atrial fibrillation (NVAF) patients in real-world clinical practice.
250 patients treated with rivaroxaban undergoing AF-ablation procedure are expected to be enrolled in two years. The patients can arrive already taking rivaroxaban or if they are naïve, the investigators will start the therapy and taking rivaroxaban for at least 4 weeks. The decision to prescribe rivaroxaban is under discretion of the treating physician, including the dose and duration of therapy. Also the decision on the ablation technique and energy used during the procedure (radiofrequency catheter ablation or Cryoballoon Ablation) is up to the investigators.
Because this study is intended to assess the use of rivaroxaban in routine real-world clinical practice, study protocol will not interfere with the clinical management of patients or with the prescribing behaviors of attending physicians.
IRIS study will include all consenting patients and collect data at the following time points:
- One inclusion/exclusion visit at the hospital (during hospitalization or outpatient visit);
- Ablation procedure in hospital;
- One-month follow-up visit.
Baseline Data
The Following information will be collected for each enrolled patient at the initial visit:
- Patient demographics (date of birth, gender, ethnic origin, height/weight)
- Previous therapies or interventions to treat AF, including cardioversion and ablation
- AF characteristics (paroxysmal or persistent)
- Cardiovascular risk factors, concomitant cardiovascular diseases and other diseases/conditions
- Concomitant medications
- Stroke and bleeding risk profiles based on CHA2DS2 (Congestive heart failure, Hypertension, Age, Diabetes Mellitus, Stroke) - VASc27 (Vascular disease, Age, Sex) score, and HAS (Hypertension, Abnormal renal and liver function, Stroke) - BLED28 (Bleeding, Labile International Normalized Ratio, Elderly, Drugs or alcohol) score.
- Data on the AF-related diagnostic assessment, including electrocardiographic assessment, blood biochemistry, echocardiography and other diagnostic procedures, if performed as part of routine care
- Inform consent signature
Ablation procedure
- Type of Ablation procedure
- Activated Clotting Time (ACT)
- Adverse Event (AE)/Serious Adverse Event (SAE)
- Major complication events
Follow-Up Data Follow-up data at 1 month will be collected for all patients.
The following information will be obtained by phone or during a visit to the center for each enrolled patient:
- Any bleedings event described in the study protocol;
- Major complications described in the study protocol;
- Adherence to Non-VKA Oral Anticoagulant (NOACs) therapy,
- Concomitant medications;
- Concomitant procedures;
- AE/SAE.
Dates
Last Verified: | 05/31/2020 |
First Submitted: | 03/17/2020 |
Estimated Enrollment Submitted: | 03/17/2020 |
First Posted: | 03/19/2020 |
Last Update Submitted: | 06/03/2020 |
Last Update Posted: | 06/04/2020 |
Actual Study Start Date: | 05/14/2020 |
Estimated Primary Completion Date: | 02/28/2022 |
Estimated Study Completion Date: | 02/28/2022 |
Condition or disease
Intervention/treatment
Drug: Nonvalvular atrial fibrillation patients (NVAF)
Procedure: Nonvalvular atrial fibrillation patients (NVAF)
Phase
Arm Groups
Arm | Intervention/treatment |
---|---|
Nonvalvular atrial fibrillation patients (NVAF) Eligible patients comprise men and women aged 18 years or older with nonvalvular atrial fibrillation diagnosis undergoing ablation procedure. | Drug: Nonvalvular atrial fibrillation patients (NVAF) Rivaroxaban therapy for at least 4 weeks. |
Eligibility Criteria
Ages Eligible for Study | 18 Years To 18 Years |
Sexes Eligible for Study | All |
Sampling method | Probability Sample |
Accepts Healthy Volunteers | Yes |
Criteria | Inclusion Criteria: - Suitable for anticoagulant therapy and catheter ablation; - Scheduled for Non Valvular Atrial Fibrillation (NVAF) catheter ablation; - Paroxysmal or persistent NVAF; - Patient naïve or in therapy with Rivaroxaban; - Written informed consent. Exclusion Criteria: - Patients who do not agree with study inclusion; - Impossible to Non-VKA Oral Anticoagulant (NOAC); - Moderate to severe hepatic impairment; - Pregnancy or lactation; - Creatinine Clearance (CrCl) < 15 ml/min. |
Outcome
Primary Outcome Measures
1. Incidence of thromboembolic and bleeding events. [30 ± 5 days after the catheter ablation procedure.]
Secondary Outcome Measures
1. Effectiveness endpoints [30 days after the catheter ablation procedure.]
2. Ablation procedure endpoints [30 days after the catheter ablation procedure.]
Other Outcome Measures
1. Activated Clotting Time (ACT) [During the ablation procedure.]
2. Study medication adherence [At baseline and after 30 days.]